Xcout Intel
Abzena plc
Abzena plc is a life sciences group providing chemistry and biopharmaceutical research solutions. The company maintains headquarters in Cambridge, United Kingdom, and Melbourne, Australia, alongside international offices in the United States.
Subscribe to see Abzena plc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Abzena plc at a glance
Abzena plc is a pharmaceuticals and biotechnology company headquartered in United Kingdom, founded in 2002. It has raised at least $4.3M across the 2 funding rounds on record. Its most recent funding round raised $3.6M in December 2015. Xcout tracks 16 named people at Abzena plc, including Geoffrey Glass (CEO and Chairman of the Board).
Abzena plc leadership
- Geoffrey GlassCEO and Chairman of the Board
- Sean O'BrienChief Operating Officer (COO) and Site Head, San Diego Operations
- Thomas CastellanoChief Financial Officer (CFO)
- Campbell BunceChief Scientific Officer (CSO)
- Joe PrincipeChief Commercial Officer (CCO)
- Troy WrightSenior Vice President and Global Head of Quality
10 more named people on record for Abzena plc, with roles, board committees and tenure — see the full roster →
Abzena plc funding rounds
At least $4.3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $3.6M | — | |
| SEC Form D filing | $700,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Abzena plc competitors
A few of Abzena plc's closest competitors — see the full list of competitors and alternatives →
Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) based in Bangalore, India. The company delivers a comprehensive range of scientific services dedicated to developing and manufacturing small and large molecules.
Medtide Inc. operates as a contract research, development, and manufacturing organization (CRDMO), providing comprehensive services across the entire pharmaceutical lifecycle, from initial drug discovery and preclinical investigation through to clinical development and commercial-scale production. The company specializes in the synthesis of novel peptide chemical entities for discovery purposes, along with the development of peptide-based chemistry, manufacturing, and control (CMC) processes, and their subsequent commercial manufacturing. A core area of its developmental focus is on glucagon-like peptide-1 (GLP-1) molecules, which it designs for both oral and/or injectable administration. Medtide leverages a suite of proprietary research and development platforms, including OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. Its client base spans multiple regions globally, including China, the United States, Japan, Europe, South Korea, and Australia. Established in 2020 as Taide Pharmaceutical (Zhejiang) Co., Ltd, the company rebranded to Medtide Inc. in February 2023 and maintains its headquarters in Hangzhou, China.
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Aragen Life Sciences Ltd. is a pharmaceutical manufacturing and contract research and development organization (CRDMO) headquartered in Hyderabad, India.
Syngene International is a contract research, development, and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services for small molecules, biologics, and other therapeutic modalities. It serves clients in the pharmaceutical, biotechnology, nutrition, animal health, and agrochemical industries by supporting their research and commercial production needs.
Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) providing services from drug discovery to manufacturing. It serves pharmaceutical and biotech companies by offering capabilities in synthetic medicinal chemistry, biology, drug metabolism and pharmacokinetics, process development, and drug substance manufacturing.
Get Abzena plc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Abzena plc? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Abzena plc in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access